Arpita Kulshrestha

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

Vasundhra Bhandari, Arpita Kulshrestha, Deepak Kumar Deep et al. · PLoS neglected tropical diseases · 2012 · 113 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

In Vitro Susceptibility of Field Isolates of <i>Leishmania donovani</i> to Miltefosine and Amphotericin B: Correlation with Sodium Antimony Gluconate Susceptibility and Implications for Treatment in Areas of Endemicity

Dhiraj Kumar, Arpita Kulshrestha, Ruchi Singh et al. · Antimicrobial Agents and Chemotherapy · 2008 · 91 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Vacuolar ATPase ‘a2’ isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer

Arpita Kulshrestha, Gajendra K. Katara, Safaa A. Ibrahim et al. · Oncotarget · 2015 · 63 citations · Full text

Medicine, Molecular Biology, Oncology +17

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani

Arpita Kulshrestha, Vasundhra Bhandari, Rupkatha Mukhopadhyay et al. · Parasitology Research · 2012 · 63 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +14

Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani

Dhiraj Kumar, Ruchi Singh, Vasundhra Bhandari et al. · Parasitology Research · 2012 · 51 citations

Life Sciences, Microbiology, Molecular Biology +17